首页> 美国卫生研究院文献>Sarcoidosis Vasculitis and Diffuse Lung Diseases >New attempt in tuberculosis treatment: autologous cytokine-induced killer after chemotherapy treatment failure in a case of multi-drug resistant tuberculosis (MTB)
【2h】

New attempt in tuberculosis treatment: autologous cytokine-induced killer after chemotherapy treatment failure in a case of multi-drug resistant tuberculosis (MTB)

机译:结核病治疗的新尝试:在多药耐药结核病(MTB)的情况下化疗失败后自体细胞因子诱导的杀手

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 32-year-old woman was diagnosed as pulmonary tuberculosis 15 years ago and recurred several times due to long-term nonstandard treatment. Drug sensitivity test indicated that multidrug-resistant tuberculosis had emerged and we determined relevant therapeutic schedule according to this result. However, it didn’t show any amelioration of the disease after 3-month chemotherapy. We formulated 3-course CIK immunotherapy based on patient’s condition. After 3 courses of immunotherapy, we found obvious amelioration of the patient’s condition. And there was no recurrence during the follow-up in the past 3 years. Therefore, we considered that the CIK immunotherapy is an effective method for tuberculosis treatment and recurrence prevention.
机译:15年前,一名32岁的妇女被诊断为肺结核,由于长期的非标准治疗,其复发了几次。药敏试验表明已出现耐多药结核病,我们根据此结果确定了相关的治疗方案。但是,经过3个月的化疗后,该病并未得到改善。我们根据患者的病情制定了3疗程CIK免疫疗法。经过3个疗程的免疫治疗后,我们发现患者的病情明显改善。在过去的三年中,随访期间均未复发。因此,我们认为CIK免疫疗法是治疗结核病和预防复发的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号